Contrasting C4 Therapeutics (NASDAQ:CCCC) and Eloxx Pharmaceuticals (NASDAQ:ELOX)

C4 Therapeutics (NASDAQ:CCCC) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares C4 Therapeutics and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-313.35%	-42.45%	-27.55%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares C4 Therapeutics and Eloxx Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$33.67 million	6.06	-$132.49 million	($1.70)	-1.70
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	N/A	N/A

Eloxx Pharmaceuticals has lower revenue, but higher earnings than C4 Therapeutics.

Insider and Institutional Ownership

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 8.6% of C4 Therapeutics shares are held by insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

C4 Therapeutics has a beta of 2.95, suggesting that its stock price is 195% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for C4 Therapeutics and Eloxx Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	0	3	3	0	2.50
Eloxx Pharmaceuticals	0	0	0	0	0.00

C4 Therapeutics presently has a consensus price target of $11.60, suggesting a potential upside of 301.38%. Given C4 Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe C4 Therapeutics is more favorable than Eloxx Pharmaceuticals.

Summary

C4 Therapeutics beats Eloxx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.